Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2007

01-12-2007 | Epidemiology

Quantitative exploration of possible reasons for the recent improvement in breast cancer survival

Authors: Sylvie Bérubé, Louise Provencher, Jean Robert, Simon Jacob, Nicole Hébert-Croteau, Julie Lemieux, Thierry Duchesne, Jacques Brisson

Published in: Breast Cancer Research and Treatment | Issue 3/2007

Login to get access

Abstract

Objective

Breast cancer mortality has been declining in many countries including Canada because of improvements in survival. This study attempts to explain observed trends in breast cancer survival with special attention given to the role of improvements in early detection and treatment.

Methods

This study is based on 4,312 women diagnosed with primary invasive breast carcinoma treated in a Canadian breast center between 1976 and 2000 and followed to the end of 2001. Observed and relative survival rates were calculated. Multivariate relative survival regression models were used to assess trends in breast cancer survival over the study period.

Results

The proportion of women with small tumors (≤10 mm) was higher in late 1990s, while that of women with regional involvement was lower compared to earlier periods. Adjuvant chemotherapy or endocrine therapy use increased steadily from 6.6% to 84.0% during the study period. Five-year relative survival rates ranged between 82.1% and 83.7% between 1976 and 1990, and increased thereafter to reach 87.6% in 1991–95, and 92.1% in 1996–2000. During the first five years after diagnosis, women diagnosed in 1991–95 and 1996–2000 experienced a reduction in breast cancer mortality of 28% (Relative Risk (RR)= 0.72; 95% CI: 0.59–0.89) and 49% (RR = 0.51; 95% CI: 0.39–0.68) respectively compared to women diagnosed in 1976–90. Improvement in breast cancer survival in 1990’s could not be explained by characteristics of women, biology of the tumor, advancements in early detection and type of initial treatments.

Conclusion

A substantial increase in breast cancer survival was observed in the 1990s but the reasons for this improvement remain elusive. Better knowledge of these reasons could help not only to further reduce the burden related to breast cancer but also the burden related to other major cancer sites.
Literature
1.
go back to reference Institut national de cancer du Canada. Statistiques canadiennes sur le cancer 2004. Toronto, Canada, avril 2004 Institut national de cancer du Canada. Statistiques canadiennes sur le cancer 2004. Toronto, Canada, avril 2004
2.
go back to reference Bray F, McCarron P, Parkin DM (2004) The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 6:229–239PubMedCrossRef Bray F, McCarron P, Parkin DM (2004) The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 6:229–239PubMedCrossRef
3.
go back to reference Ries LAG, Eisner MP, Kosary CL et al. SEER Cancer Statistics Review, 1975–2002, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2002/, based on November 2004 SEER data submission, posted to the SEER web site 2005 Ries LAG, Eisner MP, Kosary CL et al. SEER Cancer Statistics Review, 1975–2002, National Cancer Institute. Bethesda, MD, http://​seer.​cancer.​gov/​csr/​1975_​2002/​, based on November 2004 SEER data submission, posted to the SEER web site 2005
4.
go back to reference Surveillance, Epidemiology, End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Mortality – All COD, Public-Use With State, Total U.S. (1969–2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005. Underlying mortality data provided by NCHS (www.cdc.gov/nchs) Surveillance, Epidemiology, End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Mortality – All COD, Public-Use With State, Total U.S. (1969–2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005. Underlying mortality data provided by NCHS (www.cdc.gov/nchs)
5.
go back to reference Levi F, Lucchini F, Negri E et al (2004) Trends in mortality from major cancers in the European Union, including acceding countries, in 2004. Cancer 101:2843–2850PubMedCrossRef Levi F, Lucchini F, Negri E et al (2004) Trends in mortality from major cancers in the European Union, including acceding countries, in 2004. Cancer 101:2843–2850PubMedCrossRef
6.
go back to reference Surveillance, Epidemiology, End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence – SEER 9 Regs Public-Use, Nov 2004 Sub (1973–2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005, based on the November 2004 submission Surveillance, Epidemiology, End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence – SEER 9 Regs Public-Use, Nov 2004 Sub (1973–2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005, based on the November 2004 submission
7.
go back to reference Louchini R, Beaupré M La survie reliée au cancer pour les nouveaux cas déclarés au Québec, de 1984 à 1998: Survie observée et survie relative, 2003 Louchini R, Beaupré M La survie reliée au cancer pour les nouveaux cas déclarés au Québec, de 1984 à 1998: Survie observée et survie relative, 2003
8.
go back to reference Demers A, Turner D, Mo D et al (2005) Breast cancer trends in Manitoba: 40 years of follow-up. Chronic Dis Can 26:13–19PubMed Demers A, Turner D, Mo D et al (2005) Breast cancer trends in Manitoba: 40 years of follow-up. Chronic Dis Can 26:13–19PubMed
9.
go back to reference Ugnat AM, Xie L, Semenciw R et al (2005) Survival patterns for the top four cancers in Canada: the effects of age, region and period. Eur J Cancer Prev 14:91–100PubMedCrossRef Ugnat AM, Xie L, Semenciw R et al (2005) Survival patterns for the top four cancers in Canada: the effects of age, region and period. Eur J Cancer Prev 14:91–100PubMedCrossRef
10.
go back to reference Statistique Canada Statistiques sur la survie 2005. http://www.statcan.ca/francais/freepub/84–601-XIF/2005001/survival_f.htm. Access date: August 2005 Statistique Canada Statistiques sur la survie 2005. http://​www.​statcan.​ca/​francais/​freepub/​84–601-XIF/2005001/survival_f.htm. Access date: August 2005
11.
go back to reference Ellison LF, Gibbons L (2004) Leading cancers–changes in five-year relative survival. Health Rep 15:19–32PubMed Ellison LF, Gibbons L (2004) Leading cancers–changes in five-year relative survival. Health Rep 15:19–32PubMed
12.
go back to reference Coleman MP, Gatta G, Verdecchia A et al (2003) EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol 14 Suppl (5):v128–v149PubMedCrossRef Coleman MP, Gatta G, Verdecchia A et al (2003) EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol 14 Suppl (5):v128–v149PubMedCrossRef
13.
go back to reference Kobayashi S (2004) What caused the decline in breast cancer mortality in the United Kingdom? Breast Cancer 11:156–159PubMedCrossRef Kobayashi S (2004) What caused the decline in breast cancer mortality in the United Kingdom? Breast Cancer 11:156–159PubMedCrossRef
14.
15.
go back to reference Quinn MJ (2003) Cancer trends in the United States–a view from Europe. J Natl Cancer Inst 95:1258–1261PubMed Quinn MJ (2003) Cancer trends in the United States–a view from Europe. J Natl Cancer Inst 95:1258–1261PubMed
16.
go back to reference Bloom HJ, Richardson WW (1957) Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11:359–377PubMed Bloom HJ, Richardson WW (1957) Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11:359–377PubMed
17.
go back to reference Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410PubMedCrossRef Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410PubMedCrossRef
18.
go back to reference Lawless JF (1982) Statistical models and methods for lifetime data. Wiley series in probability and mathematical statistics. New York: John Wiley and Sons Lawless JF (1982) Statistical models and methods for lifetime data. Wiley series in probability and mathematical statistics. New York: John Wiley and Sons
19.
go back to reference Ederer F, Axtell LM, Cutler SJ (1961) The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr 6:101–121PubMed Ederer F, Axtell LM, Cutler SJ (1961) The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr 6:101–121PubMed
20.
go back to reference Surv3: Relative survival analysis program. Software Malual Program version 3.01. Helsinki: Finnish Cancer Registry Surv3: Relative survival analysis program. Software Malual Program version 3.01. Helsinki: Finnish Cancer Registry
21.
go back to reference Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62PubMedCrossRef Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62PubMedCrossRef
22.
go back to reference Berrino F, Esteve J, Coleman MP (1995) Basic issues in estimating and comparing the survival of cancer patients. IARC Sci Publ:1–14 Berrino F, Esteve J, Coleman MP (1995) Basic issues in estimating and comparing the survival of cancer patients. IARC Sci Publ:1–14
23.
go back to reference Gamel JW, Vogel RL (2001) Non-parametric comparison of relative versus cause-specific survival in Surveillance, Epidemiology and End Results (SEER) programme breast cancer patients. Stat Methods Med Res 10:339–352PubMedCrossRef Gamel JW, Vogel RL (2001) Non-parametric comparison of relative versus cause-specific survival in Surveillance, Epidemiology and End Results (SEER) programme breast cancer patients. Stat Methods Med Res 10:339–352PubMedCrossRef
24.
go back to reference Capocaccia R, Gatta G, Roazzi P et al (2003) The EUROCARE-3 database: methodology of data collection, standardisation, quality control and statistical analysis. Ann Oncol 14 Suppl (5):v14–v27PubMedCrossRef Capocaccia R, Gatta G, Roazzi P et al (2003) The EUROCARE-3 database: methodology of data collection, standardisation, quality control and statistical analysis. Ann Oncol 14 Suppl (5):v14–v27PubMedCrossRef
25.
go back to reference MacMahon S, Collins R (2001) Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet 357:455–462PubMedCrossRef MacMahon S, Collins R (2001) Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet 357:455–462PubMedCrossRef
26.
go back to reference Louwman WJ, Janssen-Heijnen ML, Houterman S et al (2005) Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. Eur J Cancer 41:779–785PubMedCrossRef Louwman WJ, Janssen-Heijnen ML, Houterman S et al (2005) Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. Eur J Cancer 41:779–785PubMedCrossRef
27.
go back to reference Read WL, Tierney RM, Page NC et al (2004) Differential prognostic impact of comorbidity. J Clin Oncol 22: 3099–3103PubMedCrossRef Read WL, Tierney RM, Page NC et al (2004) Differential prognostic impact of comorbidity. J Clin Oncol 22: 3099–3103PubMedCrossRef
28.
go back to reference Houterman S, Janssen-Heijnen ML, Verheij CD et al (2004) Comorbidity has negligible impact on treatment and complications but influences survival in breast cancer patients. Br J Cancer 90:2332–2337PubMed Houterman S, Janssen-Heijnen ML, Verheij CD et al (2004) Comorbidity has negligible impact on treatment and complications but influences survival in breast cancer patients. Br J Cancer 90:2332–2337PubMed
29.
go back to reference Nagel G, Wedding U, Rohrig B et al (2004) The impact of comorbidity on the survival of postmenopausal women with breast cancer. J Cancer Res Clin Oncol 130:664–670PubMedCrossRef Nagel G, Wedding U, Rohrig B et al (2004) The impact of comorbidity on the survival of postmenopausal women with breast cancer. J Cancer Res Clin Oncol 130:664–670PubMedCrossRef
30.
go back to reference Yancik R, Wesley MN, Ries LA et al (2001) Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. Jama 285:885–892PubMedCrossRef Yancik R, Wesley MN, Ries LA et al (2001) Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. Jama 285:885–892PubMedCrossRef
31.
go back to reference Piccirillo JF, Tierney RM, Costas I et al (2004) Prognostic importance of comorbidity in a hospital-based cancer registry. Jama 291:2441–2447PubMedCrossRef Piccirillo JF, Tierney RM, Costas I et al (2004) Prognostic importance of comorbidity in a hospital-based cancer registry. Jama 291:2441–2447PubMedCrossRef
32.
go back to reference Geraci JM, Escalante CP, Freeman JL et al (2005) Comorbid disease and cancer: the need for more relevant conceptual models in health services research. J Clin Oncol 23:7399–7404PubMedCrossRef Geraci JM, Escalante CP, Freeman JL et al (2005) Comorbid disease and cancer: the need for more relevant conceptual models in health services research. J Clin Oncol 23:7399–7404PubMedCrossRef
33.
go back to reference Shen Y, Yang Y, Inoue LY et al (2005) Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 97:1195–1203PubMed Shen Y, Yang Y, Inoue LY et al (2005) Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 97:1195–1203PubMed
34.
go back to reference Kerlikowske K (1997) Efficacy of screening mammography among women aged 40 to 49 years and 50 to 69 years: comparison of relative and absolute benefit. J Natl Cancer Inst Monogr:79–86 Kerlikowske K (1997) Efficacy of screening mammography among women aged 40 to 49 years and 50 to 69 years: comparison of relative and absolute benefit. J Natl Cancer Inst Monogr:79–86
35.
go back to reference Fletcher SW, Elmore JG (2003) Clinical practice. Mammographic screening for breast cancer. N Engl J Med 348:1672–1680PubMedCrossRef Fletcher SW, Elmore JG (2003) Clinical practice. Mammographic screening for breast cancer. N Engl J Med 348:1672–1680PubMedCrossRef
36.
37.
go back to reference Zackrisson S, Andersson I, Janzon L et al (2006) Rate of over-diagnosis of breast cancer 15 years after end of Malmo mammographic screening trial: follow-up study. BMJ 332:689–692PubMedCrossRef Zackrisson S, Andersson I, Janzon L et al (2006) Rate of over-diagnosis of breast cancer 15 years after end of Malmo mammographic screening trial: follow-up study. BMJ 332:689–692PubMedCrossRef
38.
go back to reference Sant M, Allemani C, Capocaccia R et al (2003) Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe. Int J Cancer 106:416–422PubMedCrossRef Sant M, Allemani C, Capocaccia R et al (2003) Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe. Int J Cancer 106:416–422PubMedCrossRef
39.
go back to reference Hebert-Croteau N, Brisson J, Lemaire J et al (2005) The benefit of participating to clinical research. Breast Cancer Res Treat 91:279–281PubMedCrossRef Hebert-Croteau N, Brisson J, Lemaire J et al (2005) The benefit of participating to clinical research. Breast Cancer Res Treat 91:279–281PubMedCrossRef
40.
go back to reference Mauri D, Pavlidis N, Ioannidis JP (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97:188–194PubMedCrossRef Mauri D, Pavlidis N, Ioannidis JP (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97:188–194PubMedCrossRef
41.
go back to reference Tai P, Yu E, Vinh-Hung V et al (2004) Survival of patients with metastatic breast cancer: twenty-year data from two SEER registries. BMC Cancer 4:60PubMedCrossRef Tai P, Yu E, Vinh-Hung V et al (2004) Survival of patients with metastatic breast cancer: twenty-year data from two SEER registries. BMC Cancer 4:60PubMedCrossRef
42.
go back to reference Giordano SH, Buzdar AU, Smith TL et al (2004) Is breast cancer survival improving? Cancer 100:44–52PubMedCrossRef Giordano SH, Buzdar AU, Smith TL et al (2004) Is breast cancer survival improving? Cancer 100:44–52PubMedCrossRef
43.
go back to reference Berry DA, Cronin KA, Plevritis SK et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784–1792PubMedCrossRef Berry DA, Cronin KA, Plevritis SK et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784–1792PubMedCrossRef
44.
go back to reference Reynolds T (1999) Declining breast cancer mortality: what’s behind it? J Natl Cancer Inst 91:750–753PubMedCrossRef Reynolds T (1999) Declining breast cancer mortality: what’s behind it? J Natl Cancer Inst 91:750–753PubMedCrossRef
45.
go back to reference Olivotto IA, Bajdik CD, Plenderleith IH et al (1994) Adjuvant systemic therapy and survival after breast cancer. N Engl J Med 330:805–810PubMedCrossRef Olivotto IA, Bajdik CD, Plenderleith IH et al (1994) Adjuvant systemic therapy and survival after breast cancer. N Engl J Med 330:805–810PubMedCrossRef
46.
go back to reference Elkin EB, Hudis C, Begg CB et al (2005) The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975–1999. Cancer 104:1149–1157 PubMedCrossRef Elkin EB, Hudis C, Begg CB et al (2005) The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975–1999. Cancer 104:1149–1157 PubMedCrossRef
47.
go back to reference Huiart L, Bardou VJ, Puig B et al (2006) [Improvement in breast cancer survival between 1975 and 2003 in a cohort of 5722 women]. Bull Cancer 93:391–399PubMed Huiart L, Bardou VJ, Puig B et al (2006) [Improvement in breast cancer survival between 1975 and 2003 in a cohort of 5722 women]. Bull Cancer 93:391–399PubMed
Metadata
Title
Quantitative exploration of possible reasons for the recent improvement in breast cancer survival
Authors
Sylvie Bérubé
Louise Provencher
Jean Robert
Simon Jacob
Nicole Hébert-Croteau
Julie Lemieux
Thierry Duchesne
Jacques Brisson
Publication date
01-12-2007
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2007
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-007-9503-1

Other articles of this Issue 3/2007

Breast Cancer Research and Treatment 3/2007 Go to the issue

Preclinical Study/Clinical Trial/Epidemiology/Invited Commentary

G:C > A:T mutations and potential epigenetic regulation of p53 in breast cancer

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine